Brought to you by 
Amgen, Servier take options to each other's cardiovascular compounds; deal terminated
23 Dec 2020
Executive Summary
Amgen Inc. has licensed US rights to Servier SA’s ivabradine, an If inhibitor that is sold in the EU and over 100 countries across the globe as Procoralan for chronic heart failure and stable angina in patients experiencing increased heart rates.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Product or Technology Swap
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen, Servier take options to each other's cardiovascular compounds; deal terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice